Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

详细信息    查看全文

• 作者：Tadaaki Arizumi (1)
  Kazuomi Ueshima (1)
  Haruhiko Takeda (2)
  Yukio Osaki (2)
  Masahiro Takita (1)
  Tatsuo Inoue (1)
  Satoshi Kitai (1)
  Norihisa Yada (1)
  Satoru Hagiwara (1)
  Yasunori Minami (1)
  Toshiharu Sakurai (1)
  Naoshi Nishida (1)
  Masatoshi Kudo (1)
  
• 关键词：Hypervascular lesion ; Liver cirrhosis ; Response evaluation criteria in solid tumors ; Response evaluation criteria in cancer of the liver ; Tumor viability
• 刊名：Journal of Gastroenterology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：49
• 期：12
• 页码：1578-1587
• 全文大小：691 KB
• 参考文献：1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-6. CrossRef
  2. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-0. CrossRef
  3. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology. 2011;81:24-. CrossRef
  4. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-0. CrossRef
  5. Rini BI. Sorafenib. Expert Opin Pharmacother. 2006;7:453-1. CrossRef
  6. Wu H, Huang C, Chang D. Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol. 2008;4:37-5.
  7. Kano MR, Komuta Y, Iwata C, et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009;100:173-0. CrossRef
  8. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009;100:1-. CrossRef
  9. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-7. CrossRef
  10. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-4. CrossRef
  11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-0. CrossRef
  12. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-11. CrossRef
  13. The Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara; 2009 (revised version).
  14. Miller AB, Hogestraeten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-4. CrossRef
  15. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97:1042-0. CrossRef
  
• 作者单位：Tadaaki Arizumi (1)
  Kazuomi Ueshima (1)
  Haruhiko Takeda (2)
  Yukio Osaki (2)
  Masahiro Takita (1)
  Tatsuo Inoue (1)
  Satoshi Kitai (1)
  Norihisa Yada (1)
  Satoru Hagiwara (1)
  Yasunori Minami (1)
  Toshiharu Sakurai (1)
  Naoshi Nishida (1)
  Masatoshi Kudo (1)
  
  1. Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, Osaka, 589-8511, Japan
  2. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-53 Fudegasaki-cho, Tennoji-ku, Osaka, 543-8555, Japan
  
• ISSN：1435-5922

文摘

Background To test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS). Methods The therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1?month was evaluated using the RECIST1.1, mRECIST, and RECICL. After categorization as showing progressive disease (PD), stable disease (SD), or objective response, the association between OS and categorization was examined using the Kaplan–Meier method to develop survival curves. The 141 cases categorized as PD or SD by the RECIST1.1, but objective response by the mRECIST and RECICL, were further analyzed for determination of the association between OS and categorization. Results Only categorization using the RECICL was found to be significantly correlated with OS (p?=?0.0033). Among the patients categorized as SD or PD by the RECIST1.1, reclassification by the RECICL but not the mRECIST was found to be significantly associated with OS and allowed for precise prediction of prognosis (p?=?0.0066). Conclusions Only the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response.